肝胆肿瘤分子诊断临床应用专家共识

肝癌电子杂志 ›› 2020, Vol. 7 ›› Issue (1): 24-31.

肝胆肿瘤分子诊断临床应用专家共识

欧美同学会医师协会肝胆分会, 中国研究型医院分子诊断医学专业委员会, 中国临床肿瘤学会肝癌专家委员会, 中国预防医学学会肝胆胰疾病预防与控制专业委员会, 亚太肝病诊疗技术联盟肝癌专业委员会

收稿日期:2020-02-05 出版日期:2020-03-30 发布日期:2020-07-17
通讯作者: 陆荫英 E-mail: luyinying1973@163.com
基金资助:
精准医学国家重点专项计划（2017YFC0908401）“十三五”国家科技（传染病）重大专项课题（2018ZX10723204-007-002,2018ZX10302205-001）

Consensus for clinical application of molecular diagnosis on hepatobiliary carcinoma

Society for hepatobiliary, Medical society of western retuned scholars association; Society for molecular diagnosis, Chinese research hospital Association, SMD/CRHA; Expert committee for liver cancer, Chinese society of clinical oncology; Professional committee for the prevention, control of hepatobiliary, pancreatic diseases, Chinese preventive medicine association; Expert committee for liver cancer, Asia pacific alliance of liver diseases

Received:2020-02-05 Online:2020-03-30 Published:2020-07-17

摘要/Abstract

摘要： 为规范肝胆系统原发恶性肿瘤相关分子标志物在临床诊断、疗效评估及预后预测等方面的应用,本共识分别从外周血及组织学水平,针对近年来研究结果较为明确的肝胆肿瘤相关蛋白质、基因表达层面的分子标志物,在诊断、治疗、分子分型方面的研究进展及临床应用指导意义等做了详尽的总结,提出了专家指导意见。同时对肝胆肿瘤相关血清学、组织病理学、二代测序等实验室检测的标准、结果判读、报告内容及全过程质量管理等也提出了规范化的建议;旨在为一线临床工作人员普及肝胆肿瘤分子诊疗最新知识的基础上,提供科学、合理选择个体化精准诊疗方案的可执行依据。

关键词: 肝胆肿瘤, 分子标志物, 临床诊断, 疗效评估, 靶向治疗, 免疫治疗, 专家共识

欧美同学会医师协会肝胆分会, 中国研究型医院分子诊断医学专业委员会, 中国临床肿瘤学会肝癌专家委员会, 中国预防医学学会肝胆胰疾病预防与控制专业委员会, 亚太肝病诊疗技术联盟肝癌专业委员会. 肝胆肿瘤分子诊断临床应用专家共识[J]. 肝癌电子杂志, 2020, 7(1): 24-31.

参考文献

[1] Trevisani F, D’Intino PE, Morselli-Labate AM, et al.Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status[J]. J Hepatol, 2001, 34(4), 570-575.
[2] Yi X,Yu S,Bao Y.Alpha-fetoprotein-L3 in hepatocellular carc-inoma: a meta-analysis[J]. Clinica Chimica Acta , 2013, 425(21): 212-220.
[3] Kokudo N, Hasegawa K, Akahane M, et al.Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res, 2015, 45(2): 123-127.
[4] Koh WJ, Greer BE, Abu-Rustum NR, et al.Vulvar Cancer, Version 1.2017[J]. J Natl Compr Canc Netw. 2017, 15(1): 92-120.
[5] 中国抗癌协会,肝门部胆管癌规范化诊治专家共识 (2015).[J] 中华肝胆外科杂志 , 2015, 21(8): 505-511.
[6] Marrero JA, Romano PR, Nikolaeva O, et al.GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma[J]. J Hepatol, 2005, 43(6): 1007-1012.
[7] Geramizadeh B, Seirfar N.Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver[J]. Hepat Mon, 2015, 15(7): e30336.
[8] Cohen JD, Li L, Wang Y, et al.Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378): 926-939.
[9] Qu C, Wang Y, Wang P, et al.Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Nat Acad Sci, 2019, 116(13): 6308-6312.
[10] Xu RH, Wei W, Krawczyk M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16: 1155-1161.
[11] Cheng JM, Wei DK, Ji Y, et al.Integrative Analysis of DNA Methylation and Gene Expression Reveals Hepatocellular Carcinoma Specific Diagnostic Biomarkers[J]. Genome Med, 10(1), 42-48.
[12] Qu Y, Shi L, Wang D, et al.Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers[J]. Int J Cancer, 2014, 134(12): 2993-2994.
[13] Zhou J, Yu L, Gao X, et al.Plasma MicroRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma[J]. Clin Oncol, 2011, 29(36): 4781-4788.
[14] Ji J, Shi J, Budhu A, et al.MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer[J]. N Engl J Med, 2009, 361(15): 1437-1447.
[15] Zucman-Rossi J, Villanueva A, Nault JC, et al.Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5):1226-123.
[16] Horwitz E, Stein I, Ben-Neriah Y, et al.Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma[J]. Mol Cell Oncol, 2015, 2(1): e968028.
[17] Lim HY, Heo J, Choi HJ, et al.A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23): 5976-5985.
[18] Xiang Q, Chen W, Ren M, et al.Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET[J]. Clin Cancer Res, 2014, 20(11): 2959-2970.
[19] Harding JJ, Nandakumar S, Armenia J, et al.Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies[J]. Clin Cancer Res, 2019, 25(7): 2116-2126.
[20] SL Zhou, ZJ Zhou, ZQ Hu, et al.Genomic Sequencing Identifies WNK2 as a Driver in hepatocellular carcinoma and a Risk Factor for Early Recurrence[J]. J Hepatol, 2019, 71(6): 1152-1163.
[21] Leijen S, Van Geel RM, Pavlick AC, et al.Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors[J]. J Clin Oncol, 2016, 34(36): 4371-4380.
[22] The Cancer Genome Atlas Research Network. Comprehensive and Integrative genomic characterization of hepatocellular carcinoma[J]. Cell, 2017, 169(7): 1327-1341.
[23] Razumilava N, Gores GJ.Cholangiocarcinoma[J]. Lancet, 2014, 383(9935): 2168-2179.
[24] Jiao Y, Pawlik TM, Anders RA, et al.Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas[J]. Nature Genetics, 2013, 45(12): 1470-1473.
[25] Wardell CP, Fujita M, Yamada T, et al.Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations[J]. J Hepatol, 2018, 68(5): 959-969.
[26] Lau DK, Tay RY, Yeung YH, et al.Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study[J]. Br J Cancer, 2018, 118(7): 966-971.
[27] George S, Miao D, Demetri GD, et al.Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma[J]. Immunity, 2017, 46(2): 197-204.
[28] Lin J, Shi J, Guo H, et al.Alterations in DNA Damage Repair Genes in Primary Liver Cancer[J]. Clin Cancer Res, 2019, 25(15): 4701-4711.
[29] Javle M, Bekaii-Saab T, Jain A, et al.Biliary cancer: Utility of nextgeneration sequencing for clinical management[J]. Cancer, 2016, 122(24): 3838-3847.
[30] Saha SK, Zhu AX, CS Fuchs, et al.Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise[J]. Oncologist, 2016, 21(5): 594-599.
[31] M Javle, M Lowery, RT Shroff, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma[J]. J Clin Oncol, 2018, 36(3): 276-282.
[32] AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium[J]. Cancer Discov, 2017, 7(8): 818-831.
[33] Javle M, Churi C, Kang HC, et al.HER2/neu-directed therapy for biliary tract cancer[J]. J Hematol Oncol, 2015, 8: 58.
[34] Sorscher S.Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab[J]. J Hematol Oncol, 2013, 9: 1-3.
[35] Law LY.Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma[J]. J Clin Oncol, 2012, 30(27): 271-273.
[36] Goeppert B, Frauenschuh L, Renner M, et al.BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma[J]. Modern Pathology, 2014, 27(7): 1028-1034.
[37] Flaherty KT, Infante JR, Daud A, et al.Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations[J]. N Engl J Med, 2012, 367(18): 1694-1703.
[38] Gang C, Huang AC, Wei Z, et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560(7718): 382-386.
[39] Le DT, Uram JN, Wang H, et al.PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. New England Journal of Medicine, 2015, 372(26): 2509-2520.
[40] Ang C, Klempner SJ, Ali SM, et al.Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma[J]. Oncotarget, 2019, 10(40): 4018-4025.
[41] Mou H, Yu L, Liao Q, et al.Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report[J]. BMC Cancer, 2018, 18(1): 1105.
[42] Havel JJ, Chowell D, Chan TA.The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nature Reviews Cancer, 2019, 19(3): 133-150.
[43] Pinyol R, Sia D, Llovet JM.Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC[J]. Clin Cancer Res, 2019, 25(7): 2021-2023.
[44] 谭卫峰, 刘庆猛, 何平生 . 免疫组化质量控制的标准化管理[C]. 卫生政策与管理 , 2013, 51(31): 134-139.
[45] 中华人民共和国国家技术监督检验检疫总局,中国国家标准化管理委员会.GB19489-2008实验室生物安全通用要求[S].北京:中国标准出版社, 2008.
[46] 《临床分子病理实验室二代基因测序检测专家共识》编写组. 临床分子病理实验室二代基因测序检测专家共识[S]. 中华病理学杂志, 2017, 46(3): 145-148.
[47] Villanueva A.Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462.
[48] O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167.
[49] Champiat S, Dercle L, Ammari S, et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/ PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-1928.
[50] Ferrara R, Mezquita L, Texier M, et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy[J]. JAMA Oncol, 2018, 4(11): 1543-1552.
[51] Kato S, Goodman A, Walavalkar V, et al.Hyper-progressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate[J]. Clin Cancer Res, 2017, 23(15), 4242-4250.